Immunotherapy as an adjunct to highly-active antiretroviral therapy.

Murphey-Corb, M; Heydenburg-Fuller, D

Murphey-Corb, M; Heydenburg-Fuller, D.

Afiliación

Murphey-Corb M; University of Pittsburgh School of Medicine, Department of Molecular Genetics and Biochemistry, Biomedical Science Tower, Room E1252, Pittsburgh, PA 15261, USA. mcorb+@pitt.edu

Curr Opin Investig Drugs ; 2(9): 1191-7, 2001 Sep.

Article en En | MEDLINE | ID: mdl-11717803

RESUMEN

Highly-active antiretroviral therapy (HAART) suppresses HIV viral replication and restores immune function in HIV-infected individuals, but HIV-1 can still persist in circulating, resting CD4+ T-cells. Recent studies demonstrate that adjunct immunotherapeutic strategies that enhance T-cell responses during HAART can, in certain cases, promote continued immune control of the AIDS virus after drugs are discontinued. However, development of immunotherapeutic strategies that target and eliminate the reservoir of HIV-1 infected, quiescent T-cells will likely be needed to achieve long-term control and eradication of the AIDS virus.

Asunto(s)

Terapia Antirretroviral Altamente Activa; Infecciones por VIH/terapia; VIH-1; Inmunoterapia; Animales; Terapia Combinada; Infecciones por VIH/tratamiento farmacológico; Humanos; Linfocitos T/efectos de los fármacos; Linfocitos T/inmunología; Replicación Viral

Buscar en Google

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Infecciones por VIH / VIH-1 / Terapia Antirretroviral Altamente Activa / Inmunoterapia Límite: Animals / Humans Idioma: En Revista: Curr Opin Investig Drugs Asunto de la revista: TERAPIA POR MEDICAMENTOS Año: 2001 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido

Buscar en Google

Añadir a Mi BVS

Imprimir

XML

PubMed Links